Select a Region North America

Insights

Insights From Our Experts

Articles

Artificial Intelligence and Machine Learning Use in Patient Safety

The next several decades will bring increased use and advancement of technology, particularly with regard to Artificial Intelligence (AI) and Machine Learning (ML) within our personal lives and in the pharmaceutical industry.   Generally, the ways…

Seven Challenges Traditional Omnichannel Tactics Cannot Overcome

How pharma companies utilize omnichannel is a significant factor in their brand’s success, especially as traditional efforts continue becoming more and more obsolete and rejected by patients and providers. Many manufacturers are facing pivotal decisions about…

The Future of Omnichannel is Here. Don’t Get Left Behind.

The standard for omnichannel continues to evolve whether pharma companies like it or not. A next-gen approach to this crucial component of the patient journey is essential to maximize success and best optimize valuable assets.  In…

Create a Comprehensive Experience by Optimizing Forward-thinking Omnichannel Strategies

Deploying successful omnichannel strategies requires manufacturers to evaluate their tactics and ensure they are meeting patients’ and providers’ needs in a modern and effective way. In this article, we lay out a check list of criteria…

Critical Success Factors for Launching Products with Fast Track, PRIME, or ILAP Designation

Launching Fast Track, PRIME, and ILAP therapies successfully requires careful planning and execution. This white paper provides insights on how to shape the product’s trajectory and control its success. It emphasizes the importance of early planning,…

Read Now: Role of Decentralized Trials for Newer Drug Approvals
Role of Decentralized Trials for Newer Drug Approvals

Decentralized clinical trials (DCTs) are an innovative approach to conducting clinical research where aspects of the trial are carried out remotely, allowing patients to participate from their homes or local healthcare facilities. DCTs offer several advantages…

Matching-Adjusted Indirect Comparison (MAIC): An Established Methodology for Comparing Treatment Efficacies Across Trials

In the realm of comparative effectiveness research (CER), decision-makers often face challenges when attempting to compare treatment efficacies due to limited availability of comparative data, especially for new therapies. This white paper introduces the Matching-Adjusted Indirect…

Navigating an Ever-evolving Canadian Market Access and Reimbursement Environment

These are just some of the trends currently shaping the Canadian market access environment. Achieving favourable market access and reimbursement outcomes for new treatments in this ever-changing landscape requires intimate knowledge of the Canadian landscape, processes…

From Limitations to Expansions: How Prioritizing Patients’ Speed to Therapy Drives Therapy Adoption

Navigating the launch of a new product is a complex and ever-evolving journey for manufacturers. With hundreds of millions of dollars and an abundance of other significant resources invested in a product’s pre-launch commercialization efforts, meeting…

Case Study: Primary Research Meets Data-Driven Sources and Technology to Form Powerful Market Access Solutions

The case for primary market research, Real-World Data (RWD), and deep healthcare experience combined to deliver targeted market access strategies. As diseases become more complex and market access becomes more restrictive, with multiple sources of market…